RORA1 mRNA の発現とメチル化割合との相関
非癌部と比べて癌部において有意にメチル化割合が高かった群（非癌部＜癌部）の RNAを抽
出し得た 14症例において、RORA1 プロモーターのメチル化の割合の比（癌部/非癌部）と、
癌部におけるRORA1 mRNAの発現（A）、またはmRNAの発現量の比（癌部/非癌部）(B)の
いずれも有意に逆相関した。（p=0.044, p=0.041）
31 0.000
0.005 0.010 0.015 0.020 0.025
N2 N8 N13 N17 N19 N20 N22 N24 N25 T1 T2 T4 T5 T6 T7 T8 T9 T10 T11
T12 T13 T15 T16 T17 T18 T19 T20 T21 T22 T23 T24 T25 T26 T27 T28
RORA4 mRNA䛾Ⓨ⌧
図 1 ２
RORA4 mRNA の発現解析
大腸癌切除検体における、非癌部および癌部のRORA4 mRNAの発現を定量的RT-PCRに より解析した結果を示す。発現レベルはGAPDHを内部コントロールとして標準化した。
32
図１３
大腸癌の病期と癌部の RORA1 プロモーターのメチル化割合の関連
癌部と非癌部のメチル化割合に有意差のあった（非癌部＜癌部）群 18 例について、各症例の病
期Ⅱ、病期Ⅲおよび病期Ⅳの癌部におけるメチル化割合を示す。各病期における癌部のメチル化
割合の平均値の差が統計的に有意かどうかを確かめるために、有意水準5%で両側検定のt検定を行
ったところ、病期Ⅱと病期Ⅲとでは、t (10)= 2.42, p =0.036 と有意差をみとめた。
!"
!#$"
!#%"
!#&"
!#'"
("
(#$"
" " "
!"!"#$#%&
33
RORA1䝥䝻䝰䞊䝍䞊
䝯䝏䝹 ṇᖖ ⭠⒴䚷ᮇ㻌I 䞉㻌II ᮇ III䞉㻌IV 㧗
RORA1Ⓨ⌧ • ᰁⰍయᏳᐃᛶ䠛
• 䝠䝇䝖䞁ಟ㣭䠛
図１４
正常~進行大腸癌における RORA1 プロモーターのメチル化と発現との関係
34
␒ྕ ᖺ㱋 㼀㻹㻺ᮇ Ⓨ⌧㔞㻔㻺㻕 Ⓨ⌧㔞㻔㼀㻕 Ⓨ⌧㔞㻔㼀㻛㻺㻕 䝯䝏䝹ྜ䠄㻺䠅 䝯䝏䝹ྜ䠄㼀䠅 䝯䝏䝹ྜ䠄㼀㻛㻺䠅
㻝 㻣㻤 㻵㻵㻵㻮 0.071558069 㻣㻚㻤㻠㻠㻤㻱㻙㻜㻡 㻜㻚㻜㻜㻝㻜㻥㻢㻞㻥㻝 㻜㻚㻞㻝 㻜㻚㻝㻤 㻜㻚㻤㻡㻣㻝㻠㻞㻤㻡㻣
㻞 㻡㻥 䊡㻭 㻥㻚㻤㻢㻣㻞㻠㻱㻙㻜㻡 㻝㻚㻜㻡㻥㻞㻱㻙㻜㻡 㻜㻚㻝㻜㻣㻟㻠㻤㻥㻟 㻜㻚㻝㻡 㻜㻚㻡㻢 㻟㻚㻣㻟㻟㻟㻟㻟㻟㻟㻟
㻟 㻣㻜 䊢㻮 㻜㻚㻠㻢㻜㻣㻞㻢㻜㻣㻟 㻝㻚㻜㻟㻜㻜㻥㻣㻤㻞 㻞㻚㻞㻟㻡㻤㻝㻠㻜㻟㻞 㻜㻚㻞㻤 㻜㻚㻤㻞 㻞㻚㻥㻞㻤㻡㻣㻝㻠㻞㻥
㻠 㻢㻞 䊢㻮 㻺㻭 㻺㻭 㻺㻭 㻜㻚㻝㻠 㻜㻚㻜㻤 㻜㻚㻡㻣㻝㻠㻞㻤㻡㻣㻝
㻡 㻡㻥 䊢㻮 㻜㻚㻜㻜㻤㻥㻥㻞㻜㻥㻥 㻡㻚㻝㻥㻣㻠㻱㻙㻜㻡 㻜㻚㻜㻜㻡㻣㻣㻥㻥㻟㻡 㻜㻚㻞 㻜㻚㻟㻢 㻝㻚㻤
㻢 㻤㻣 䊡㻭 㻝㻚㻡㻥㻟㻟㻡㻠㻠㻟 㻜㻚㻜㻜㻜㻝㻝㻢㻞㻥 㻣㻚㻞㻥㻤㻠㻠㻱㻙㻜㻡 㻜㻚㻞㻞 㻜㻚㻣㻢 㻟㻚㻠㻡㻠㻡㻠㻡㻠㻡㻡
㻣 㻡㻣 䊢㻮 0.043926884 0.00071484 㻜㻚㻜㻝㻢㻞㻣㻟㻠㻥㻝 㻜㻚㻝㻢 㻜㻚㻞㻠 㻝㻚㻡
㻤 㻢㻤 䊢㻮 㻜㻚㻜㻜㻡㻣㻜㻝㻠㻣㻥 㻜㻚㻜㻜㻜㻞㻢㻜㻥㻥 㻜㻚㻜㻠㻡㻣㻣㻢㻠㻠㻞 㻜㻚㻞㻠 㻜㻚㻝㻟 㻜㻚㻡㻠㻝㻢㻢㻢㻢㻢㻣
㻥 㻡㻡 䊢㻯 㻜㻚㻞㻞㻢㻝㻤㻡㻡㻟㻠 㻜㻚㻜㻜㻜㻢㻝㻟㻡㻤 㻜㻚㻜㻜㻞㻣㻝㻞㻣㻞㻤 㻜㻚㻝㻢 㻜㻚㻡㻣 㻟㻚㻡㻢㻞㻡
㻝㻜 㻢㻤 䊢㻭 㻜㻚㻜㻜㻠㻣㻡㻢㻣㻝㻝 㻜㻚㻜㻜㻞㻝㻜㻠㻣㻠 㻜㻚㻠㻠㻞㻠㻣㻣㻤㻤㻢 㻜㻚㻞㻤 㻜㻚㻞㻟 㻜㻚㻤㻞㻝㻠㻞㻤㻡㻣㻝
㻝㻝 㻣㻟 䊣 㻜㻚㻜㻜㻜㻢㻣㻣㻤㻠㻟 㻜㻚㻜㻜㻜㻞㻟㻢㻞㻡 㻜㻚㻟㻠㻤㻡㻞㻣㻞㻥㻢 㻜㻚㻡㻣 㻜㻚㻥㻢 㻝㻚㻢㻤㻠㻞㻝㻜㻡㻞㻢
㻝㻞 㻣㻡 䊡㻭 㻜㻚㻜㻜㻝㻤㻡㻢㻣㻣㻠 㻠㻚㻡㻣㻝㻤㻱㻙㻜㻡 㻜㻚㻜㻞㻠㻢㻞㻞㻜㻥㻟 㻜㻚㻠㻟 㻜㻚㻢㻥 㻝㻚㻢㻜㻠㻢㻡㻝㻝㻢㻟
㻝㻟 㻣㻢 䊢㻮 㻜㻚㻜㻜㻜㻣㻞㻠㻤㻠㻤 㻜㻚㻜㻜㻜㻞㻤㻞㻠 㻜㻚㻟㻤㻥㻢㻜㻠㻣㻝㻢 㻜㻚㻝㻝 㻜㻚㻠㻤 㻠㻚㻟㻢㻟㻢㻟㻢㻟㻢㻠
㻝㻠 㻢㻥 䊡㻭 㻜㻚㻤㻝㻣㻠㻞㻢㻟㻤㻞 㻜㻚㻜㻜㻝㻝㻢㻡㻜㻞 㻜㻚㻜㻜㻝㻠㻞㻡㻞㻞㻠 㻜㻚㻟 㻜㻚㻤㻣 㻞㻚㻥
㻝㻡 㻤㻜 䊢㻮 㻜㻚㻜㻟㻞㻢㻜㻥㻜㻢㻡 㻜㻚㻜㻜㻜㻢㻢㻣㻟 㻜㻚㻜㻞㻜㻠㻢㻟㻢㻠㻢 㻜㻚㻞㻞 㻜㻚㻡㻠 㻞㻚㻠㻡㻠㻡㻠㻡㻠㻡㻡
㻝㻢 㻣㻡 䊡㻭 㻺㻭 㻺㻭 㻺㻭 㻜㻚㻞㻝 㻺㻭 㻺㻭
㻝㻣 㻣㻢 䊡㻭 㻜㻚㻜㻜㻜㻟㻝㻝㻞㻞㻡 㻝㻚㻜㻥㻜㻞㻱㻙㻜㻡 㻜㻚㻜㻟㻡㻜㻞㻥㻝㻥㻠 㻜㻚㻞㻠 㻜㻚㻤㻡 㻟㻚㻡㻠㻝㻢㻢㻢㻢㻢㻣
㻝㻤 㻤㻢 䊡㻭 㻜㻚㻜㻜㻠㻥㻟㻝㻡㻡㻣 㻜㻚㻜㻜㻜㻝㻟㻟㻜㻝 㻜㻚㻜㻞㻢㻥㻣㻜㻢㻥㻟 㻜㻚㻞㻢 㻜㻚㻝㻝 㻜㻚㻠㻞㻟㻜㻣㻢㻥㻞㻟
㻝㻥 㻢㻜 䊢㻮 㻜㻚㻜㻜㻜㻞㻝㻜㻞㻜㻟 㻜㻚㻜㻜㻜㻞㻟㻟㻤 㻝㻚㻝㻝㻞㻞㻢㻞㻣㻢㻠 㻜㻚㻝㻣 㻜㻚㻝㻝 㻜㻚㻢㻠㻣㻜㻡㻤㻤㻞㻠
㻞㻜 㻣㻜 䊣 㻞㻚㻞㻣㻣㻜㻞㻱㻙㻜㻡 㻡㻚㻟㻝㻠㻝㻱㻙㻜㻡 㻞㻚㻟㻟㻟㻣㻤㻡㻣㻝㻝 㻜㻚㻞㻝 㻜㻚㻟㻡 㻝㻚㻢㻢㻢㻢㻢㻢㻢㻢㻣
㻞㻝 㻤㻟 䊢㻮 㻜㻚㻝㻠㻡㻝㻥㻟㻠㻞㻝 㻣㻚㻤㻣㻣㻡㻱㻙㻜㻡 㻜㻚㻜㻜㻜㻡㻠㻞㻡㻡 㻜㻚㻞 㻜㻚㻢㻡 㻟㻚㻞㻡
㻞㻞 㻡㻡 䊣 㻺㻭 㻺㻭 㻺㻭 㻜㻚㻝㻡 㻺㻭 㻺㻭
㻞㻟 㻣㻡 䊡㻭 㻜㻚㻜㻜㻜㻣㻟㻡㻟㻜㻝 㻢㻚㻢㻢㻞㻞㻱㻙㻜㻡 㻜㻚㻜㻥㻜㻢㻜㻠㻥㻡㻞 㻜㻚㻝㻢 㻜㻚㻤㻤 㻡㻚㻡
㻞㻠 㻣㻟 䊡㻭 㻜㻚㻜㻜㻜㻟㻞㻞㻟㻡㻟 㻣㻚㻢㻢㻥㻥㻱㻙㻜㻡 㻜㻚㻞㻟㻣㻥㻟㻡㻝㻣㻟 㻜㻚㻞 㻜㻚㻞 㻝
㻞㻡 㻣㻢 䊡㻭 㻺㻭 㻺㻭 㻺㻭 㻜㻚㻞㻝 㻜㻚㻢㻞 㻞㻚㻥㻡㻞㻟㻤㻜㻥㻡㻞
㻞㻢 㻣㻢 䊡㻭 㻝㻚㻟㻤㻝㻜㻢㻱㻙㻜㻡 㻜㻚㻜㻜㻜㻝㻡㻜㻟㻠 㻝㻜㻚㻤㻤㻢㻜㻞㻢㻣㻥 㻜㻚㻝㻤 㻜㻚㻝㻢 㻜㻚㻤㻤㻤㻤㻤㻤㻤㻤㻥
㻞㻣 㻢㻥 䊣 㻜㻚㻜㻜㻜㻞㻡㻢㻤㻥㻟 㻞㻚㻠㻠㻞㻱㻙㻜㻡 㻜㻚㻜㻥㻡㻜㻡㻣㻝㻣㻣 㻜㻚㻝㻞 㻜㻚㻝㻟 㻝㻚㻜㻤㻟㻟㻟㻟㻟㻟㻟
㻞㻤 㻢㻝 䊣 㻥㻚㻡㻥㻤㻠㻞㻱㻙㻜㻡 㻝㻚㻤㻠㻜㻝㻱㻙㻜㻡 㻜㻚㻝㻥㻝㻣㻜㻣㻣㻣㻡 㻜㻚㻝㻢 㻜㻚㻝㻝 㻜㻚㻢㻤㻣㻡
㻞㻥 㻢㻡 㻵㻵㻭 NA 㻺㻭 㻺㻭 㻜㻚㻞㻞 㻜㻚㻞 㻜㻚㻥㻜㻥㻜㻥㻜㻥㻜㻥
㻟㻜 㻣㻝 㻵㻵㻭 NA 㻺㻭 㻺㻭 㻜㻚㻝㻣 㻜㻚㻡㻞 㻟㻚㻜㻡㻤㻤㻞㻟㻡㻞㻥
㻟㻝 㻢㻤 㻵㼂 NA 㻺㻭 㻺㻭 㻜㻚㻟 㻜㻚㻞㻟 㻜㻚㻣㻢㻢㻢㻢㻢㻢㻢㻣
㻟㻞 㻠㻤 㻵㻵㻭 NA 㻺㻭 㻺㻭 㻜㻚㻝㻢 㻜㻚㻞㻟 㻝㻚㻠㻟㻣㻡
㻟㻟 㻟㻢 㻵㻵㻭 NA 㻺㻭 㻺㻭 㻜㻚㻞 㻜㻚㻞㻡 㻝㻚㻞㻡
㻟㻠 㻢㻤 㻵㻵㻵㻮 NA 㻺㻭 㻺㻭 㻜㻚㻝㻞 㻜㻚㻝㻠 㻝㻚㻝㻢㻢㻢㻢㻢㻢㻢㻣
㻟㻡 㻣㻡 㻵㼂 NA 㻺㻭 㻺㻭 㻜㻚㻝㻥 㻜㻚㻣㻝 㻟㻚㻣㻟㻢㻤㻠㻞㻝㻜㻡
㻟㻢 㻢㻞 㻵㻵㻵㻮 NA 㻺㻭 㻺㻭 㻜㻚㻞㻞 㻜㻚㻝㻤 㻜㻚㻤㻝㻤㻝㻤㻝㻤㻝㻤
㻟㻣 㻢㻤 㻵㼂 NA 㻺㻭 㻺㻭 㻜㻚㻝㻢 㻜㻚㻞㻟 㻝㻚㻠㻟㻣㻡
㻟㻤 㻤㻞 㻵㻵㻭 NA 㻺㻭 㻺㻭 㻜㻚㻝㻥 㻜㻚㻞㻞 㻝㻚㻝㻡㻣㻤㻥㻠㻣㻟㻣
㻟㻥 㻡㻤 㻵 NA 㻺㻭 㻺㻭 㻜㻚㻞㻟 㻜㻚㻡㻤 㻞㻚㻡㻞㻝㻣㻟㻥㻝㻟
㻠㻜 㻡㻤 㻵 NA 㻺㻭 㻺㻭 㻜㻚㻝㻥 㻜㻚㻝㻟 㻜㻚㻢㻤㻠㻞㻝㻜㻡㻞㻢
㻠㻝 㻢㻞 㻵㻵㻵㻮 NA 㻺㻭 㻺㻭 㻜㻚㻝㻟 㻜㻚㻝㻟 㻝
㻠㻝 㻢㻡 㻵㻵㻭 NA 㻺㻭 㻺㻭 㻜㻚㻞㻣 㻜㻚㻟㻠 㻝㻚㻞㻡㻥㻞㻡㻥㻞㻡㻥
㻠㻟 㻡㻤 㻵㼂 NA 㻺㻭 㻺㻭 㻜㻚㻝㻠 㻜㻚㻝㻣 㻝㻚㻞㻝㻠㻞㻤㻡㻣㻝㻠
補足資料
N: 大腸正常粘膜、 T: 大腸癌、 NA: 測定不能
35
【引用文献】
1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;
61:759-767.
3. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R.Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines.
Cancer Res 1997; 57:808-811.
4. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55:4525-4530.
5. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG.
Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res. 2000; 60:129-133.
6. Shen L,Kondo Y, Ronsner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, BuckmeierJ, Alberts DS, Hamilton SR, Issa JP.
MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005; 97:1330-1338.
7. Moinova HR, Chen WD, Shen L, Smiraglia D, Olechnowicz J, Ravi L, Kasturi L, Myeroff L, Plass C, Parsons R, Minna J, Willson JK,Green SB, Issa JP, Markowitz SD.
HLTF gene silencing in human colon cancer. Proc Natl Acad Sci USA 2002;
99:4562-4567.
8. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135:1079-1799.
36
9. Shinojima Y, Terui T, Hara H, Kimura M, Igarashi J, Wang X, Kawashima H, Kobayashi Y, Muroi S, Hayakawa S, Esumi M, Fujiwara K, Ghosh S, Yamamoto T, Held W, Nagase H.
Identification and analysis of an early diagnostic marker for malignant melanoma: ZAR1 intra-genic differential methylation. J Dermatol Sci. 2010; 59:98-106.
10. Watanabe T, Yachi K, Ohta T, Fukushima T, Yoshino A, Katayama Y, Shinojima Y, Terui T, Nagase H. Aberrant hypermethylation of non-promoter zygote arrest 1 (ZAR1) in human brain tumors. Neurol Med Chir. 2010; 50:1062-1069.
11. Fujiwara K, Ghosh S, Liang P, Morien E, Soma M, Nagase H. Genome-wide screening of aberrant DNA methylation which associated with gene expression in mouse skin cancers. Mol Carcinog. 2015; 54:178-188.
12. Sugito K, Kawashima H, Uekusa S, Yoshizawa S, Hoshi R, Furuya T, Kaneda H, Hosoda T, Masuko T, Ohashi K, Ikeda T, Koshinaga T, Fujiwara K, Igarashi J, Ghosh S, Held WA, Nagase H. Identification of aberrant methylation regions in neuroblastoma by screening of tissue-specific differentially methylated regions.
Pediatr Blood Cancer. 2013; 60:383-389.
13. Kottorou AE, Antonacopoulou AG, Dimitrakopoulos FI, Tsamandas AC, Scopa CD, Petsas T, Kalofonos HP. Altered expression of NFY-C and RORA in colorectal adenocarcinomas. Acta Histochem. 2012; 114:553-561.
14. Becker-André M, André E, DeLamarter JF. Identification of nuclear receptor mRNAs by RT-PCR amplification of conserved zinc-finger motif sequences. Biochem Biophys Res Commun. 1993; 194:1371-1379.
15. Carlberg C, Hooft van Huijsduijnen R, Staple JK, DeLa-marter JF and Becker-Andre M, RZRs, a New Family of Retinoid Related Orphan Receptors That Function as both Monomers and Homodimers. 1993; Mol. Endocrinol. 8:757-770.
16. Giguere V, Tini M, Flock G, Ong E, Evans RM, Otulakowski G. Isoform-specific
37
amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of orphan hormone nuclear receptors. Genes Dev. 1994; 8:538-553.
17. Steinmayr M, André E, Conquet F, Rondi-Reig L, Delhaye-Bouchaud N, Auclair N, Daniel H, Crépel F, Mariani J, Sotelo C, Becker-André M. staggerer phenotype in retinoid-related orphan receptor alpha-deficient mice. Proc Natl Acad Sci USA. 1998;
95:3960-3965.
18. Kallen J, Schlaeppi JM, Bitsch F, Delhon I, Fournier B. Crystal structure of the human RORalpha Ligand binding domain in complex with cholesterol sulfate at 2.2 A.
J Biol Chem. 2004; 279:14033-14038.
19. Wiesenberg I, Missbach M, Kahlen JP, Schrader M, Carlberg C. Transcriptional activation of the nuclear receptor RZR alpha by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res. 1995;
23:327-333.
20. Lee JM, Kim IS, Kim H, Lee JS, Kim K, Yim HY, Jeong J, Kim JH, Kim JY, Lee H, Seo SB, Kim H, Rosenfeld MG, Kim KI, Baek SH. RORalpha attenuates Wnt/beta-catenin signaling by PKCalpha-dependent phosphorylation in colon cancer.
Mol Cell. 2010; 37:183- 195.
21. Kim H, Lee JM, Lee G, Bhin J, Oh SK, Kim K, Pyo KE, Lee JS, Yim HY, Kim KI, Hwang D, Chung J, Baek SH. DNA damage-induced RORalpha is crucial for p53 stabilization and increased apoptosis. Mol Cell. 2011; 44:797-810.
22. Delerive P, Monté D, Dubois G, Trottein F, Fruchart- Najib J, Mariani J, Fruchart JC, Staels B. The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response. EMBO Rep. 2001; 2:42-48.
23. Chauvet C, Bois-Joyeux B, Danan JL. Retinoic acid receptor-related orphan receptor (ROR) alpha4 is the predominant isoform of the nuclear receptor RORalpha in the
38
liver and is up-regulated by hypoxia in HepG2 human hepatoma cells. Biochem J.
2002; 364:449-456.
24. Chauvet C, Bois-Joyeux B, Berra E, Pouyssegur J, Danan JL. The gene encoding human retinoic acid-receptor-related orphan receptor alpha is a target for hypoxia-inducible factor 1. Biochem J. 2004; 384:79-85.
25. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK, van den Boom D. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A. 2005;
102:15785-15790.
26. Issa, J.P., Ottaviano, Y.L., Celano, P., Hamilton, S.R., David- son, N.E., & Baylin, S.B.
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet. 1994; 7:536-540.
27. Issa, J.P., Ahuja, N., Toyota, M., Bronner, M.P., & Brentnall, T.A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001;
61:3573―3577.
28. Xiong G, Wang C, Evers BM, Zhou BP, Xu R. RORalpha suppresses breast tumor invasion by inducing SEMA3F expression. Cancer Res. 2012; 72:1728-1739.
29. Moretti RM, Marelli MM, Motta M, Polizzi D, Monestiroli S, Pratesi G, Limonta P, Activation of the orphan nuclear receptor RORalpha induces growth arrest in androgen-independent DU 145 prostate cancer cells. Prostate 2001; 46:327-335
30. Zhu Y, McAvoy S, Kuhn R, Smith DI. RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene. 2006; 25:2901-2908
31. Knudoson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68:820-823
32. Migita H, Satozawa N, Lin JH, Morser J, Kawai K. RORα1 and RORα4 suppress